Rhavdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin

Canadian Journal of Clinical Pharmacology

Volumn 16, Issue 1, 2009, Pages

  Sawant, R D ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Ciprofloxacin; Elderly; Polypharmacy; Rhabdomyolysis; Simvastatin

Indexed keywords

ABC TRANSPORTER; ACETYLSALICYLIC ACID; CIMETIDINE; CIPROFLOXACIN; CYTOCHROME P450 3A4; FUROSEMIDE; ISOSORBIDE MONONITRATE; LEVOTHYROXINE; METHYLPREDNISOLONE; NICORANDIL; PINDOLOL; SIMVASTATIN; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; ENZYME INHIBITOR;

AGED; ARTICLE; CASE REPORT; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; FEMALE; HUMAN; MUSCLE BIOPSY; PHYSIOTHERAPY; POLYPHARMACY; RHABDOMYOLYSIS; URINARY TRACT INFECTION; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; METABOLISM;

AGED; ANTI-INFECTIVE AGENTS; ANTILIPEMIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CIPROFLOXACIN; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; RHABDOMYOLYSIS; SIMVASTATIN;

EID: 60849102788     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Nies AS, Spielberg SP. Principles of therapeutics. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill International edition; 1996. p.43-62.
2. Roland M, Tozer TN. Variability. In: Roland M, Tozer TN, editors. Clinical pharmacokinetics. 2nd ed. Philadelphia: Lea andFebiger; 1989. p.197-212.
3. Herman RJ. Drug interactions and statins. CMAJ 1999;161(10):1281-6.
4. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988;62:28J-34J.
5. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian simvastatin survival study. Arch Intern Med 1996;156:2085-92.
6. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988;319:24-33.
7. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Safety 2000; 22:441-457.
8. Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 2003 July; 56(1):120-124.
9. Holtzman CW, Wiggins B, Spinler S. Role of p-gp in statin drug interactions. Pharmacotherapy.2006; 26:(11):1601-1607.
10. Alvarez AI, Pérez M, Prieto JG, Molina AJ, Real R, Merino G. Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci 2008 Sep; 97 (9):3483-93.